These findings provide a rationale for multiple ongoing clinical studies investigating the efficacy and safety of gedatolisib (PI3Kα inhibitor) in combination with anti-CTLA-4 mAB in patients with metastatic BC [119]. This evidence concerns the gene CTLA4 and breast cancer.